AusBiotech is calling for innovative approaches, contributions or analyses to include in its October 2020 edition of the Australasian Biotechnology journal.
AusBiotech is welcoming abstracts from valued members on set themes, including innovative vaccine development, building sovereign capability, investment, and clinical trials: how they’ve adapted to the new conditions of COVID-19 and how the lessons learnt can be applied into the future, as life sciences ensures its rightful place as a key and growing economic and social driver.
The journal will also feature a sneak peek into the AusBiotech + Invest 2020 premier annual conference, where global leaders will also contribute as to how our industry has responded and pulled together in its ‘finest hour’.
Australasian Biotechnology is AusBiotech’s official biannual journal, and published in October and April. Its contributions are written by the sector, for the sector.
With its informed and authoritative editorials, Australasian Biotechnology is a highly-effective communications vehicle for those wanting to reach out to stakeholders in the life sciences sector.The journal is mailed on a name-and-title basis to over 3,000 AusBiotech members and investors. Readership includes companies, government and university departments, research institutes, biotechnology and professional services providers nationally, and in key overseas markets.
Abstracts can be sent to Karen Parr, Director, Communications, by 16 July 2020.
If your abstract is accepted, the full article will be required on or before 31 July 2020. Article lengths are approximately 500 words (1 page) or 1,000 words (2 pages). High resolution photos to accompany articles are encouraged.
Articles are a member-benefit, however there is limited space and so are not guaranteed to be included. Abstracts are welcomed on research, business news, and sector trends for consideration at any time of the year.